Using rhTPO to improve stem cell collection for leukemia patients
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests whether a drug called rhTPO can help collect your own stem cells for a transplant to treat acute leukemia. The goal is to improve stem cell collection so the transplant can be more successful.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 65 years old.
- You must have acute leukemia that is in complete remission, with no minimal residual disease (MRD) detected.
- You should be generally active and able to care for yourself (ECOG performance status less than 2).
- You must have normal liver and kidney function (no severe organ failure).
- You must not have active infections, allergies to rhTPO, or a history of blood clots.
- You must be willing to sign a consent form and follow the study plan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving a medicine called rhTPO early can help prevent low blood platelets, a common side effect of the chemotherapy used to prepare your body for a stem cell transplant. The goal is to help you recover faster and reduce the need for platelet transfusions.
This trial studies whether “TPO” medicines (like eltrombopag or similar drugs) help people age 14 and older with primary immune thrombocytopenia (ITP) who did not respond well to first treatments. It may help raise platelet counts and reduce bleeding, especially when prior therapy hasn’t worked.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
This trial tests if combining two platelet-raising drugs (TPO and a TPO receptor agent) can help patients with solid tumors who have very low platelets after cancer treatment. It aims to prevent or treat severe platelet drops.
This trial tests if romiplostim, a drug that helps the body make platelets, can speed up platelet recovery after a special type of stem cell transplant from a half-matched donor. It may help reduce bleeding risk during the recovery period.
This Phase 2 study tests a strong (myeloablative) stem cell transplant using donor stem cells (allogeneic transplant) for certain blood and bone marrow cancers. The goal is to see how well this approach works and whether it can improve outcomes for people who need transplant-level treatment.
Hear when a new Hematopoietic Stem Cell Mobilization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.